SLC5A2 and kidney disorder: In particular, in patients with atherosclerotic cardiovascular disease or at high cardiovascular risk, and in patients with cardiac decompensation or renal disease, SGLT-2 inhibitors and GLP-1 agonists are recommended, with proven cardiovascular benefit [54].